<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ther Adv Respir Dis</journal-id><journal-id journal-id-type="iso-abbrev">Ther Adv Respir Dis</journal-id><journal-id journal-id-type="publisher-id">TAR</journal-id><journal-id journal-id-type="hwp">sptar</journal-id><journal-title-group><journal-title>Therapeutic Advances in Respiratory Disease</journal-title></journal-title-group><issn pub-type="ppub">1753-4658</issn><issn pub-type="epub">1753-4666</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27480166</article-id><article-id pub-id-type="pmc">5933620</article-id><article-id pub-id-type="doi">10.1177/1753465816661091</article-id><article-id pub-id-type="publisher-id">10.1177_1753465816661091</article-id><article-categories><subj-group subj-group-type="heading"><subject>Reviews</subject></subj-group></article-categories><title-group><article-title>Nivolumab in the treatment of metastatic squamous non-small cell lung
cancer: a review of the evidence</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lim</surname><given-names>Joline S. J.</given-names></name><aff id="aff1-1753465816661091">Cancer Science Institute of Singapore, National
University of Singapore, Singapore</aff></contrib><contrib contrib-type="author"><name><surname>Soo</surname><given-names>Ross A.</given-names></name><xref ref-type="corresp" rid="corresp1-1753465816661091"/><aff id="aff2-1753465816661091">Department of Haematology&#x02013;Oncology, National
University Cancer Institute, National University Health System, 1E Kent
Ridge Road, NUHS Tower Block Level 7, Singapore 119228</aff></contrib></contrib-group><author-notes><corresp id="corresp1-1753465816661091"><email>ross_soo@nuhs.edu.sg</email></corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2016</year></pub-date><volume>10</volume><issue>5</issue><fpage>444</fpage><lpage>454</lpage><permissions><copyright-statement>&#x000a9; The Author(s), 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 3.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/3.0/">http://www.creativecommons.org/licenses/by-nc/3.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access page (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract><p>Progress in the treatment of patients with advanced stage squamous cell non-small
cell lung cancer (NSCLC) has been limited. An improvement in the understanding
of tumor immunosurveillance has resulted in the development of the immune
checkpoint inhibitors such as nivolumab. Nivolumab (Opdivo<sup>&#x000ae;</sup>), a human
immunoglobulin (Ig)G4 anti-programmed death (PD)-1 monoclonal antibody, was the
first PD-1 inhibitor approved in the treatment of patients with advanced stage
squamous cell NSCLC following platinum-based chemotherapy. CHECKMATE 017, a
randomized phase III study of second-line nivolumab <italic>versus</italic>
docetaxel, significantly improved overall survival (OS), progression-free
survival (PFS), patient reported outcomes and the safety and tolerability
favored patients treated with nivolumab. The ligand (PD-L1) expression did not
predict for outcome. In this paper, we review the role of nivolumab in the
treatment of NSCLC with particular attention on recent studies, ongoing
combination studies, toxicity profile, current and potential predictive
biomarkers.</p></abstract><kwd-group><kwd>anti-programmed death-1</kwd><kwd>immunotherapy</kwd><kwd>nivolumab</kwd><kwd>non-small cell lung cancer</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="section1-1753465816661091"><title>Introduction</title><p>Although the field of immune-oncology has been ongoing for more than a decade, only
more recently has it generated great interest with the efficacy of immune checkpoint
inhibitors (ICI). Ipilimumab, a cytotoxic T-cell Lymphocyte Antigen 4 (CTLA4)
inhibitor, was amongst the first ICI to be approved by the United States (US) Food
and Drug Administration (FDA), and this was subsequently followed by other ICIs such
as antibodies against both programmed-cell death-protein 1 (PD-1) and its ligand
(PD-L1). The ICIs have been shown to be effective in a range of hematological and
solid tumors, including melanomas, non-small cell lung cancer (NSCLC), renal cell
carcinoma and lymphomas [<xref rid="bibr34-1753465816661091" ref-type="bibr">Sundar
<italic>et al.</italic> 2015</xref>]. Nivolumab (BMS-936558), an anti-PD-1
antibody, was the first in its class to be approved by the US FDA in the second-line
treatment of patients with advanced stage NSCLC (both squamous [<xref rid="bibr8-1753465816661091" ref-type="bibr">Brahmer <italic>et al.</italic>
2015</xref>] and nonsquamous [<xref rid="bibr6-1753465816661091" ref-type="bibr">Borghaei <italic>et al.</italic> 2015</xref>] histologies) after progression on
platinum-based chemotherapy. Nivolumab is a human immunoglobulin (Ig)G4 anti-PD-1
monoclonal antibody. It acts by binding to PD-1, an inhibitory co-receptor expressed
on antigen-activated T cells, thus preventing interaction with PD-L1, resulting in
the loss of inhibitory signals in T cells, and tumor recognition by cytotoxic T
cells and thus restoring T-cell function (<xref ref-type="fig" rid="fig1-1753465816661091">Figure 1</xref>) [<xref rid="bibr38-1753465816661091" ref-type="bibr">Wang <italic>et al.</italic> 2014</xref>]. In this
article, we review the current standard of care for treatment of squamous NSCLC, the
role of nivolumab in its treatment, toxicities and management of treatment-related
adverse events.</p><fig id="fig1-1753465816661091" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Mechanism of action of nivolumab.</p><p>The TCR signaling pathway is a major component of immune defense against
tumors. Under normal circumstances, TCR recognition of the MHC on APCs will
trigger a cascade of events causing activation of T cells and thus immune
response against tumor cells. This signal is inhibited by tumor cells with
activation of the PD-1/PD-L1 inhibitor co-signaling pathway, which
ameliorates T-cell activation. Nivolumab acts by binding onto the PD-L1 on T
cells, thus preventing inhibitor co-signaling and restoring T-cell
activation.</p><p>APC, antigen presenting cell; MHC, major histocompatibility complex; PD-1,
programmed death-1; PD-L1, programmed death-1 ligand; TCR, T-cell
receptor.</p></caption><graphic xlink:href="10.1177_1753465816661091-fig1"/></fig></sec><sec id="section2-1753465816661091"><title>Treatment of squamous non-small cell lung cancer</title><p>Adenocarcinoma and squamous cell carcinoma (SCC) histologic subtypes comprise 60&#x02013;70%
and 10&#x02013;20% of NSCLC, respectively [<xref rid="bibr13-1753465816661091" ref-type="bibr">De la Cruz <italic>et al.</italic> 2011</xref>].
The survival of patients with adenocarcinoma has improved. Patients with NSCLC
adenocarcinoma treated with agents targeting tumor-specific oncogenes had a median
survival of 3.5 years [<xref rid="bibr22-1753465816661091" ref-type="bibr">Kris
<italic>et al.</italic> 2014</xref>]. However, unlike adenocarcinoma,
therapeutic progress in SCC of the lung has lagged, in part due to the paucity of
relevant oncogenic drivers that can inform treatment. This evidence suggests that
new drugs for metastatic squamous NSCLC are needed. The treatment of nonsquamous
NSCLC has seen significant progress in the past decade with the identification of
molecular subtypes [<xref rid="bibr23-1753465816661091" ref-type="bibr">Kumarakulasinghe <italic>et al.</italic> 2015</xref>]. Data from the Cancer
Genome Atlas Research Network (TCGA) showed significant differences in genetic
profiles between the two most common histological subtypes of lung cancer,
adenocarcinoma and SCC [<xref rid="bibr10-1753465816661091" ref-type="bibr">Cancer
Genome Atlas Research, 2012</xref>, <xref rid="bibr11-1753465816661091" ref-type="bibr">2014</xref>]. Overall, 62% of lung adenocarcinomas
harbored known activating mutations in driver oncogenes, including mutations in the
epidermal growth factor receptor (EGFR) gene and echinoderm microtubule-associated
protein-like 4 &#x02013; anaplastic lymphoma kinase (EML4-ALK) and ROS1 gene fusion and the
use of tyrosine kinase inhibitors (TKIs) towards target proteins [<xref rid="bibr11-1753465816661091" ref-type="bibr">Cancer Genome Atlas Research,
2014</xref>]. However similar driver mutations are uncommonly observed in SCCs
[<xref rid="bibr10-1753465816661091" ref-type="bibr">Cancer Genome Atlas
Research, 2012</xref>]. As such, platinum-based doublet chemotherapy, such as
carboplatin/ paclitaxel or gemcitabine/ cisplatin has remained the mainstay of
first-line treatment of squamous NSCLC [<xref rid="bibr2-1753465816661091" ref-type="bibr">Ang <italic>et al.</italic> 2015</xref>]. Recently,
the addition of necitumumab, a second-generation EGFR monoclonal antibody, showed
significant improvement in progression-free survival (PFS) (5.7
<italic>versus</italic> 5.5 months, 95% CI 0.74&#x02013;0.98, <italic>p</italic> = 0.02)
and overall survival (OS) (11.5 <italic>versus</italic> 9.9 months, 95% CI
0.74&#x02013;0.96, <italic>p</italic> = 0.01) when added to the platinum doublet of
cisplatin-gemcitabine in patients with metastatic SCC lung [<xref rid="bibr35-1753465816661091" ref-type="bibr">Thatcher <italic>et al.</italic> 2015</xref>].
Further analysis of correlation between EGFR expression by IHC scoring and FISH
analysis suggest possible predictive values towards response, although this will
need to be further validated. Nonetheless, necitumumab is the first drug that has
been approved in first-line treatment for SCC lung since the use of platinum-based
doublet therapy in the past decade.</p><p>Traditionally the median OS in patients treated with second-line therapy for advanced
NSCLC is about 8 months, with docetaxel the most frequent chemotherapy of choice
[<xref rid="bibr31-1753465816661091" ref-type="bibr">Shepherd <italic>et
al.</italic> 2000</xref>; <xref rid="bibr21-1753465816661091" ref-type="bibr">Kim <italic>et al.</italic> 2008</xref>].
Nonetheless, recent pooled analysis from various second-line docetaxel studies have
suggested that patients with squamous histology tend to do worse than those with
nonsquamous histologies, amidst already dismal survival improvements [<xref rid="bibr37-1753465816661091" ref-type="bibr">Torri <italic>et al.</italic>
2015</xref>]. In a phase III study of second-line docetaxel and ramucirumab
<italic>versus</italic> docetaxel (REVEL study), OS favored the combination arm
with an OS of 10.5 <italic>versus</italic> 9.1 months [hazard ratio (HR) 0.86, 95%
CI 0.75&#x02013;0.98]. In the 26% of patients with SCC, the HR for OS was 0.761 (95% CI
0.606&#x02013;0.957) [<xref rid="bibr15-1753465816661091" ref-type="bibr">Garon <italic>et
al.</italic> 2014</xref>]. In a phase III study of docetaxel and nintedanib
<italic>versus</italic> docetaxel, among patients with SCC lung (42%), the
addition of nintedanib was associated with a PFS of HR 0.77 (95% CI 0.62&#x02013;0.96), and
an OS of HR 1.01 (95%CI 0.85&#x02013;1.21, <italic>p</italic> = 0.891) [<xref rid="bibr27-1753465816661091" ref-type="bibr">Reck <italic>et al.</italic>
2014</xref>]. In a phase III study of second-line afatinib
<italic>versus</italic> erlotinib, the median PFS was 2.6
<italic>versus</italic> 1.9 months (HR 0.81, 95% CI 0.69&#x02013;0.96,
<italic>p</italic> = 0.0103), and OS was 7.92 <italic>versus</italic> 6.77
months (HR 0.808, 95% CI 0.691&#x02013;0.946, <italic>p</italic> = &#x02009;0.0077) [<xref rid="bibr32-1753465816661091" ref-type="bibr">Soria <italic>et al.</italic>
2015</xref>]. In these studies, the survival benefit, whilst statistically
significant, is only modest and novel therapeutic approaches are needed. The success
of ICIs in melanoma has led to its use in other solid tumors including NSCLC.</p></sec><sec id="section3-1753465816661091"><title>Nivolumab in lung cancer</title><p>Nivolumab (Opdivo<sup>&#x000ae;</sup>, Bristol Myers Squibb, USA) was the first ICI to be
approved by the US FDA in the treatment of SCC lung in March 2015, with its approval
extended to lung cancers of nonsquamous histologies in October 2015 [<xref rid="bibr34-1753465816661091" ref-type="bibr">Sundar <italic>et al.</italic>
2015</xref>]. In addition, nivolumab has been approved by the US FDA for the
following indications: unresectable or metastatic melanoma, classical Hodgkin&#x02019;s
lymphoma after failure of more than two treatment lines, second-line treatment of
advanced renal cell carcinoma, and in combination with ipilimumab, a CTLA-4
inhibitor, in metastatic melanoma irrespective of BRAF status.</p><p>Pembrolizumab (Keytruda<sup>&#x000ae;</sup>, Merck, USA), another anti-PD-1 agent, was
approved by the US FDA in October 2015 for use in a second-line setting post
platinum-based chemotherapy for patients with metastatic NSCLC whose tumors express
PD-L1.</p><p>The first in-human studies of nivolumab carried out were basket trials carried out in
refractory solid tumors, of which 15.4% patients (six out of 39) had NSCLC [<xref rid="bibr36-1753465816661091" ref-type="bibr">Topalian <italic>et al.</italic>
2012</xref>]. Patients on the study received a single dose of nivolumab at doses
ranging from 0.3&#x02013;10 mg/kg with provision for a repeat dose at 3-month intervals for
patients who derived clinical benefit. Although drug efficacy was not the primary
endpoint in this phase I trial, significant tumor regression was seen in one of the
six patients with NSCLC, despite the fact that lung cancers were not known to be
classically immunogenic compared with tumors like renal cell carcinomas and
melanomas. The drug was well tolerated and maximum tolerated dose (MTD) was not
reached, with only one patient developing the serious adverse event (SAE) of
inflammatory colitis [<xref rid="bibr7-1753465816661091" ref-type="bibr">Brahmer
<italic>et al.</italic> 2010</xref>].</p><p>Based on these results, a dose-expansion cohort of patients with NSCLC were enrolled
into trial. Of these 129 patients enrolled, 54 patients (41.2%) had SCC lung. The
overall response rate (ORR) was 17% across all cohorts, and median OS was 9.9
months, with median survival in the 3 mg/kg cohort performing best at 14.9 months
[Gettinger <italic>et al.</italic> 2015]. This was similar for both patients with
squamous and nonsquamous histology. PD-L1 expression status did not appear to
predict for tumor response, and subgroup analysis suggest that better responses were
seen in former and current smokers (ORR 30% in patients with smoking history of more
than 5 pack-years <italic>versus</italic> 0% in patients with smoking history of 5
pack-years or less) [<xref rid="bibr16-1753465816661091" ref-type="bibr">Gettinger
<italic>et al.</italic> 2015a</xref>]. Based on the promising results,
subsequent phase II studies with nivolumab at a dose of 3 mg/kg every 2 weeks were
conducted.</p><p>In a phase II single-arm study (CHECKMATE 063), 117 patients with advanced stage
squamous cell NSCLC were treated with nivolumab in third-line and beyond. The ORR
was 14.5%, 26% of patients had stable disease and the 6-month and 12-month PFS was
25.9% and 20.0% [<xref rid="bibr28-1753465816661091" ref-type="bibr">Rizvi
<italic>et al.</italic> 2015</xref>]. These results were noteworthy given
65% of patients were previously treated with three or more lines of systemic
therapy, and in 61% of patients, disease progression was the best response to the
most recent treatment. Updated survival results presented recently reported an OS of
8.2 months and 1-year OS rate of 41% [<xref rid="bibr19-1753465816661091" ref-type="bibr">Horn <italic>et al.</italic> 2015</xref>]. In a
Japanese phase II study (ONO-4538-05), of patients with advanced stage SCC lung
(<italic>n</italic> = 35) and nonsquamous lung cancer (<italic>n</italic> = 76)
treated with nivolumab, the ORR was 25.7% in the SCC group. In addition, the disease
control rate (DCR) of 54.3% and the PFS of 4.2 months. The OS was not reached [<xref rid="bibr25-1753465816661091" ref-type="bibr">Nakagawa <italic>et al.</italic>
2015</xref>] (<xref ref-type="table" rid="table1-1753465816661091">Table
1</xref>). In another phase II study conducted at community research sites
(CHECKMATE 153, CA209-153) patients with advanced stage NSCLC were treated with
nivolumab till progression or unacceptable toxicities compared with being treated
for a maximum of 1 year, then discontinuation with an intention to restart nivolumab
at progression. Of the 824 patients enrolled, 227 patients (28%) had a SCC
histologic subtype. The ORR and stable disease at first assessment was 13% and 50%,
respectively, in patients with squamous cell NSCLC [<xref rid="bibr20-1753465816661091" ref-type="bibr">Hussein <italic>et al.</italic> 2015</xref>].
While the second study involved patients with both squamous and nonsquamous
subtypes, both phase II studies supported that nivolumab was effective in patients
with SCC lung compared with historical outcomes of patients on conventional
chemotherapy. As such, further phase III trial was undertaken for patients with SCC
lung.</p><table-wrap id="table1-1753465816661091" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Trials of nivolumab in SCC lung.</p></caption><alternatives><graphic xlink:href="10.1177_1753465816661091-table1"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Phase</th><th align="left" rowspan="1" colspan="1">Author</th><th align="left" rowspan="1" colspan="1">Line of treatment</th><th align="left" rowspan="1" colspan="1">Sample size</th><th align="left" rowspan="1" colspan="1">ORR (%)</th><th align="left" rowspan="1" colspan="1">PFS (months) (95% CI)</th><th align="left" rowspan="1" colspan="1">OS (months) (95% CI)</th><th align="left" rowspan="1" colspan="1">Limitations</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">I</td><td rowspan="1" colspan="1">Topalian NEJM2012 [<xref rid="bibr36-1753465816661091" ref-type="bibr">Topalian <italic>et
al.</italic> 2012</xref>], Gettinger JCO2015 [Gettinger
<italic>et al.</italic> 2015]</td><td rowspan="1" colspan="1">Second line and beyond</td><td rowspan="1" colspan="1">54</td><td rowspan="1" colspan="1">16.7</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">9.2 (7.3&#x02013;12.5)</td><td rowspan="1" colspan="1">Small sample size<break/>Multiple treatment lines</td></tr><tr><td rowspan="1" colspan="1">I</td><td rowspan="1" colspan="1">Gettinger ASCO2015 [Gettinger <italic>et al.</italic> 2015]</td><td rowspan="1" colspan="1">First line</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">18.2 (CI not reported)</td><td rowspan="1" colspan="1">Small sample size<break/>First line only</td></tr><tr><td rowspan="1" colspan="1">II (CHECKMATE 063)</td><td rowspan="1" colspan="1">Rizvi Lancet 2015 [<xref rid="bibr28-1753465816661091" ref-type="bibr">Rizvi <italic>et al.</italic>
2015</xref>]</td><td rowspan="1" colspan="1">Third line and beyond</td><td rowspan="1" colspan="1">117</td><td rowspan="1" colspan="1">14.5</td><td rowspan="1" colspan="1">1.9 (1.8&#x02013;3.2)</td><td rowspan="1" colspan="1">8.2 (6.1&#x02013;10.9)</td><td rowspan="1" colspan="1">Heavily pretreated population, with 20.5% of patients having 4
or more lines of previous treatment</td></tr><tr><td rowspan="1" colspan="1">II (ONO-4538-050)</td><td rowspan="1" colspan="1">Nakagawa JTO2015 [<xref rid="bibr25-1753465816661091" ref-type="bibr">Nakagawa <italic>et
al.</italic> 2015</xref>]</td><td rowspan="1" colspan="1">Second line and beyond</td><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">25.7</td><td rowspan="1" colspan="1">4.2 (1.5&#x02013;7.1)</td><td rowspan="1" colspan="1">Not reached (12.4&#x02013;not reached)</td><td rowspan="1" colspan="1">Preliminary results<break/>Small sample size<break/>Asian
population<break/>Multiple treatment lines</td></tr><tr><td rowspan="1" colspan="1">II (CHECKMATE 153)</td><td rowspan="1" colspan="1">Hussein WLCC2015 [<xref rid="bibr20-1753465816661091" ref-type="bibr">Hussein <italic>et
al.</italic> 2015</xref>]</td><td rowspan="1" colspan="1">Second line or more</td><td rowspan="1" colspan="1">145</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Preliminary results<break/>Study compared 1 year
<italic>versus</italic> continuous nivolumab<break/>Multiple
treatment lines</td></tr><tr><td rowspan="1" colspan="1">III (CHECKMATE 017)</td><td rowspan="1" colspan="1">Brahmer NEJM2015 [<xref rid="bibr8-1753465816661091" ref-type="bibr">Brahmer <italic>et al.</italic>
2015</xref>]</td><td rowspan="1" colspan="1">Second line</td><td rowspan="1" colspan="1">272</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">3.5 (2.1&#x02013;4.9)</td><td rowspan="1" colspan="1">9.2 (7.3&#x02013;13.3)</td><td rowspan="1" colspan="1">Retrospective analysis of PD-L1 expression<break/>Compared
against docetaxel whereas newer regimens such as docetaxel +
ramucirumab is superior to docetaxel</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-1753465816661091"><p>CI, confidence interval; NA, not available; ORR, objective response rate;
OS, overall survival; PFS, progression-free survival; SCC, squamous cell
carcinoma.</p></fn></table-wrap-foot></table-wrap><p>In a phase III study of nivolumab <italic>versus</italic> docetaxel in 272 patients
with advanced SCC lung (CHECKMATE 017), the study was terminated early on the
recommendation of the independent data and safety monitoring committee as
pre-specified interim analysis succeeded in showing an improvement in their primary
endpoint of OS. The OS with nivolumab and docetaxel was 9.2 and 6.0 months,
respectively (HR 0.59, 95% CI 0.44&#x02013;0.79, <italic>p</italic> &#x0003c; 0.001) [<xref rid="bibr8-1753465816661091" ref-type="bibr">Brahmer <italic>et al.</italic>
2015</xref>]. Furthermore, the ORR and PFS favored nivolumab (20%
<italic>versus</italic> 9%, <italic>p</italic> = 0.008) and HR 0.63 (95% CI
0.48&#x02013;0.83, <italic>p</italic> &#x0003c; 0.01), respectively (<xref ref-type="table" rid="table1-1753465816661091">Table 1</xref>). Again PD-L1 expression was
neither prognostic nor predictive of outcomes. Lung Cancer Symptom Scale (LCSS)
assessment of patients showed that patients who responded to nivolumab appeared to
have a more sustained period of symptom improvement compared with patients on
docetaxel. Time to first disease deterioration measured by LSCC Global Health
Related Quality of Life was longer in patients treated with nivolumab compared with
patients treated with docetaxel (HR 0.58, 95% CI 0.39&#x02013;0.86) [<xref rid="bibr18-1753465816661091" ref-type="bibr">Gralla <italic>et al.</italic> 2015</xref>]. With
the positive outcome of this study, the US FDA approved nivolumab for the treatment
of advanced SCC lung with progression on or after platinum-based chemotherapy.
Nonetheless, certain limitations remain, including the role of PD-L1 expression as a
predictive marker, that is still an area of active investigation. While nivolumab is
superior to docetaxel, the efficacy of nivolumab compared with other recent active
combinations such as docetaxel with ramucirumab or nindetanib remains to be
seen.</p><p>Current trials are being undertaken to look at the efficacy of nivolumab compared
with platinum doublet treatment in a first-line setting. CHECKMATE026 included
patients with both squamous and nonsquamous NSCLC, has completed accrual and early
results may be made available by 2017. In the squamous cohort, patients were
randomized to either nivolumab or platinum doublet (cisplatin or carboplatin
combined with either gemcitabine or paclitaxel) with the option of crossover at
disease progression (<xref ref-type="table" rid="table2-1753465816661091">Table
2</xref>).</p><table-wrap id="table2-1753465816661091" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Combination studies of nivolumab in non-small cell lung cancer.</p></caption><alternatives><graphic xlink:href="10.1177_1753465816661091-table2"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Phase</th><th align="left" rowspan="1" colspan="1">Author</th><th align="left" rowspan="1" colspan="1">Line of treatment</th><th align="left" rowspan="1" colspan="1">Sample size</th><th align="left" rowspan="1" colspan="1">ORR (%) (range)</th><th align="left" rowspan="1" colspan="1">PFS (months) (range)</th><th align="left" rowspan="1" colspan="1">OS (months) (range)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">I</td><td rowspan="1" colspan="1">Antonia [<xref rid="bibr3-1753465816661091" ref-type="bibr">Antonia <italic>et al.</italic> 2014a</xref>]</td><td rowspan="1" colspan="1">First line with chemotherapy</td><td rowspan="1" colspan="1">56</td><td rowspan="1" colspan="1">33&#x02013;57</td><td rowspan="1" colspan="1">4.1&#x02013;6.1</td><td rowspan="1" colspan="1">50.5&#x02013;NR</td></tr><tr><td rowspan="1" colspan="1">I</td><td rowspan="1" colspan="1">Rizvi [<xref rid="bibr29-1753465816661091" ref-type="bibr">Rizvi
<italic>et al.</italic> 2014</xref>]</td><td rowspan="1" colspan="1">EGFR+ but resistant nivolumab + erlotinib</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">I</td><td rowspan="1" colspan="1">Antonia [<xref rid="bibr4-1753465816661091" ref-type="bibr">Antonia <italic>et al.</italic> 2014b</xref>]</td><td rowspan="1" colspan="1">Second line with ipilimumab</td><td rowspan="1" colspan="1">148</td><td rowspan="1" colspan="1">13&#x02013;39</td><td rowspan="1" colspan="1">4.9&#x02013;10.6</td><td rowspan="1" colspan="1">NR</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn2-1753465816661091"><p>NA, not available; NR, not reported; ORR, objective response rate; OS,
overall survival; PFS, progression-free survival.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section4-1753465816661091"><title>Rationale for combination therapy</title><p>Preclinical data have suggested that combination of ICIs with chemotherapy or other
targeted therapy like anti-angiogenic drugs may have synergistic effects. Akbay and
colleagues showed that PD-L1 expression may be upregulated <italic>via</italic> the
EGFR signaling pathway [<xref rid="bibr1-1753465816661091" ref-type="bibr">Akbay
<italic>et al.</italic> 2013</xref>], and D&#x02019;Incecco and colleagues showed
that there was a significant correlation between EGFR and KRAS mutations with PD-L1
and PD-1 expression respectively [<xref rid="bibr14-1753465816661091" ref-type="bibr">D&#x02019;Incecco <italic>et al.</italic> 2015</xref>].
The combination of nivolumab with EGFR-mutant NSCLC is being studied in patients who
are treatment na&#x000ef;ve or have progressed on first-line EGFR TKI therapy. Preliminary
results reported an ORR of 19%, 6-month PFS of 51% and 1-year OS of 73% [<xref rid="bibr29-1753465816661091" ref-type="bibr">Rizvi <italic>et al.</italic>
2014</xref>].</p><p>Conventional chemotherapy occurs largely through apoptosis, which is believed to be
nonimmunogenic compared with necrosis, which is more inflammatory in nature.
Preclinical data have shown that combination of chemotherapy with immunotherapy may
lead to more pronounced cell death due to complementary pathways in cell killing
[<xref rid="bibr5-1753465816661091" ref-type="bibr">Apetoh <italic>et
al.</italic> 2008</xref>]. The combination of nivolumab with platinum-based
doublet in the first-line setting has shown encouraging outcomes. In a phase I trial
of 56 patients with NSCLC, including both squamous and nonsquamous histology,
patients were treated with four cycles of nivolumab plus platinum-based doublet in
four different subgroups, with continuation of nivolumab alone till progression or
unacceptable toxicities. The ORR ranged from 33&#x02013;57%, PFS 21&#x02013;31 weeks and median OS
of 50.5 weeks to not reached [<xref rid="bibr4-1753465816661091" ref-type="bibr">Antonia <italic>et al.</italic> 2014b</xref>].</p><p><italic>In vitro</italic> studies have shown anti-CTLA4 and anti-PD-1 inhibition have
synergistic effects in promoting cell death. Combined PD-1 and CTLA-4 blockade has
been shown to increase effector T-cell infiltration in melanoma cells, that
eventually leads to decreased anergy and increased activity that allows for the
tumor microenvironment to shift from suppressive to inflammatory [<xref rid="bibr12-1753465816661091" ref-type="bibr">Curran <italic>et al.</italic>
2010</xref>]. Encouraging preclinical data, combined with success of combination
therapy in melanomas have fueled the extension of such studies in NSCLC.
CHECKMATE012, a phase I trial, is currently investigating the combination of
nivolumab with ipilimumab at various dose combinations. Initial results have been
encouraging with ORR range from 13&#x02013;39% and median PFS from 4.9&#x02013;10.6 months in
various treatment arms. Grade 3/4 SAEs were see in 28% of patients, including
pneumonitis, diarrhea, colitis and raised liver function, with three patient deaths
deemed attributable to drug-related toxicities, including respiratory failure
following colitis, pulmonary hemorrhage and toxic epidermal necrolysis in a patient
with history of ulcerative colitis. [Antonia <italic>et al.</italic> 2014].</p></sec><sec id="section5-1753465816661091"><title>Adverse events</title><p>Based on the mechanism of action of nivolumab, the anticipated side effects are
immune-related adverse events (irAEs). In studies of patients with NSCLC treated
with nivolumab, any grade adverse events were reported in 58&#x02013;85% of patients, while
rates of grade 3&#x02013;4 toxicities ranged from 5.7&#x02013;17% (<xref ref-type="table" rid="table3-1753465816661091">Table 3</xref>). The common side effects included
fatigue (16&#x02013;33%), anorexia (11%), diarrhea (8&#x02013;10%) and endocrinopathies [<xref rid="bibr29-1753465816661091" ref-type="bibr">Rizvi <italic>et al.</italic>
2014</xref>; <xref rid="bibr8-1753465816661091" ref-type="bibr">Brahmer
<italic>et al.</italic> 2015</xref>; <xref rid="bibr25-1753465816661091" ref-type="bibr">Nakagawa <italic>et al.</italic> 2015</xref>].</p><table-wrap id="table3-1753465816661091" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Ongoing trials of nivolumab in advanced NSCLC.</p></caption><alternatives><graphic xlink:href="10.1177_1753465816661091-table3"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Phase</th><th align="left" rowspan="1" colspan="1">Line of treatment</th><th align="left" rowspan="1" colspan="1">Control arm</th><th align="left" rowspan="1" colspan="1">Experimental arm</th><th align="left" rowspan="1" colspan="1">Clinical trial gov. number</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">I (CHECKMATE 012)</td><td rowspan="1" colspan="1">Second line and beyond</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">Nivolumab + ipilimumab, nivolumab + platinum doublet, nivolumab
+ erlotinib</td><td rowspan="1" colspan="1">NCT01454102</td></tr><tr><td rowspan="1" colspan="1">III (CHECKMATE 026)</td><td rowspan="1" colspan="1">First line</td><td rowspan="1" colspan="1">Platinum doublet</td><td rowspan="1" colspan="1">Nivolumab</td><td rowspan="1" colspan="1">NCT02041533</td></tr><tr><td rowspan="1" colspan="1">I</td><td rowspan="1" colspan="1">Second line and beyond</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">Nivolumab + EGF816 or INC280</td><td rowspan="1" colspan="1">NCT02323126</td></tr><tr><td rowspan="1" colspan="1">III (CHECKMATE 078)</td><td rowspan="1" colspan="1">Second line</td><td rowspan="1" colspan="1">Docetaxel</td><td rowspan="1" colspan="1">Nivolumab</td><td rowspan="1" colspan="1">NCT02613507</td></tr><tr><td rowspan="1" colspan="1">III (CHECKMATE 227)</td><td rowspan="1" colspan="1">First line</td><td rowspan="1" colspan="1">Platinum doublet</td><td rowspan="1" colspan="1">Nivolumab, nivolumab + ipilimumab, nivolumab + platinum
doublet</td><td rowspan="1" colspan="1">NCT02477826</td></tr><tr><td rowspan="1" colspan="1">II (CHECKMATE 568)</td><td rowspan="1" colspan="1">First line</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">Nivolumab + ipilimumab</td><td rowspan="1" colspan="1">NCT02659059</td></tr><tr><td rowspan="1" colspan="1">I</td><td rowspan="1" colspan="1">First line</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">Nivolumab + ceritinib</td><td rowspan="1" colspan="1">NCT02393625</td></tr></tbody></table></alternatives></table-wrap><p>The rate of treatment-related adverse events (TRAEs) leading to discontinuation and
death is relatively low with nivolumab. In CHECKMATE 063 [<xref rid="bibr28-1753465816661091" ref-type="bibr">Rizvi <italic>et al.</italic> 2015</xref>], 12%
and 1.7% of patients experienced TRAE discontinuation and death, respectively, and
in CHECKMATE 017 [<xref rid="bibr8-1753465816661091" ref-type="bibr">Brahmer
<italic>et al.</italic> 2015</xref>], it was 3% and 0%, respectively. In
comparison, the rate of TRAE discontinuation and death in patients treated with
docetaxel in CHECKMATE 017 was 10% and 2%, respectively. In addition, there was more
neutropenia of any grade (33% <italic>versus</italic> 1%) and febrile neutropenia
(11% <italic>versus</italic> 0%) in patients treated with docetaxel compared with
nivolumab.</p><p>Pneumonitis was the most common irAE resulting in nivolumab discontinuation.
Pneumonitis is generally mild and manageable with steroid treatment. In CHECKMATE
063, 5% of patients had pneumonitis of which 3% was grade 3 or higher. In this
study, all patients responded to steroids and the median time to resolution was 3.4
weeks (1.6&#x02013;13.4 weeks) [<xref rid="bibr28-1753465816661091" ref-type="bibr">Rizvi
<italic>et al.</italic> 2015</xref>]. In CHECKMATE 017, 5% of patients had
pneumonitis (any grade) whereas no patients had pneumonitis is the docetaxel arm. In
the phase I study, three patients had unresolved pneumonitis, resulting in mortality
[Gettinger <italic>et al.</italic> 2015]. The onset of pneumonitis may be variable.
In a recent report of patients with melanoma treated with nivolumab, the onset of
pneumonitis was 7.4&#x02013;24.3 months from treatment initiation [<xref rid="bibr26-1753465816661091" ref-type="bibr">Nishino <italic>et al.</italic> 2015</xref>].
Onset can be insidious with symptoms like cough, while others developed dyspnea and
hypoxia. Radiology may show ground glass changes with reticular opacities, although
consolidative changes were also observed in one patient. The diagnosis of
pneumonitis may be challenging in patients, especially in those with underlying
airways disease or metastases confounding underlying baseline symptoms. It may also
sometimes be difficult to discern development of pneumonitis from underlying disease
progression from description of symptoms alone. It is important to have a high
degree of suspicion and early access to imaging as this may be useful in
differentiating the etiology of worsening respiratory symptoms.</p><p>The management of irAEs include the use of steroids and in more severe cases,
immunomodulatory agents such as anti-metabolite (mycophenolate mofetil), anti-tumor
necrosis factor (TNF)-&#x003b1; antibody (infliximab) and calcineurin inhibitors (tacrolimus
and cyclosporine). Choice of steroids and immunomodulatory agents are largely
dependent on grade of side effects, and are summarized in <xref ref-type="table" rid="table4-1753465816661091">Table 4</xref> [<xref rid="bibr24-1753465816661091" ref-type="bibr">Naidoo <italic>et al.</italic> 2015</xref>; <xref rid="bibr33-1753465816661091" ref-type="bibr">Spain <italic>et al.</italic>
2016</xref>; <xref rid="bibr9-1753465816661091" ref-type="bibr">Bristol-Myers-Squibb, 2016</xref>]. While the Common Terminology Criteria for
Adverse Events (CTCAE) is the most common platform used to grade toxicities, there
have been concerns about whether it may underestimate certain toxicities like
hypophysitis. With increased understanding of irAEs, better grading systems may
eventually evolve.</p><table-wrap id="table4-1753465816661091" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Immune related adverse events (%) in patients treated with nivolumab.</p></caption><alternatives><graphic xlink:href="10.1177_1753465816661091-table4"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Study</th><th align="left" colspan="2" rowspan="1">CHECKMATE 063 [<xref rid="bibr19-1753465816661091" ref-type="bibr">Horn <italic>et al.</italic>
2015</xref>]</th><th align="left" colspan="2" rowspan="1">ONO-4538-050 [<xref rid="bibr25-1753465816661091" ref-type="bibr">Nakagawa <italic>et
al.</italic> 2015</xref>]</th><th align="left" colspan="2" rowspan="1">CHECKMATE 017 [<xref rid="bibr8-1753465816661091" ref-type="bibr">Brahmer <italic>et al.</italic>
2015</xref>]</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Immune related adverse events</td><td rowspan="1" colspan="1">All grade</td><td rowspan="1" colspan="1">Grade 3/4</td><td rowspan="1" colspan="1">Grade 3/4</td><td rowspan="1" colspan="1">Grade 3/4</td><td rowspan="1" colspan="1">All grade</td><td rowspan="1" colspan="1">Grade 3/4</td></tr><tr><td rowspan="1" colspan="1">Skin</td><td rowspan="1" colspan="1">15.5</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">28.6</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">Gastrointestinal</td><td rowspan="1" colspan="1">11.6</td><td rowspan="1" colspan="1">0.8</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">5.7</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">Pulmonary</td><td rowspan="1" colspan="1">7.0</td><td rowspan="1" colspan="1">2.3</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">5.7</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">Endocrinopathies</td><td rowspan="1" colspan="1">6.2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">11.4</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">Hepatitis</td><td rowspan="1" colspan="1">4.7</td><td rowspan="1" colspan="1">0.8</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">5.7</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">Renal injury</td><td rowspan="1" colspan="1">3.1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2.9</td><td rowspan="1" colspan="1">0</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="section6-1753465816661091"><title>Role of predictive biomarkers</title><p>In this era of precision medicine, companion diagnostics such as a validated
predictive biomarkers that may be able to help select for patients who are most
likely to respond to treatment, is paramount in optimizing patient outcomes. Studies
involving nivolumab have collected immunohistochemical (IHC) data in terms of
measurement of PD-1, PD-L1 and tumor infiltrating lymphocytes (TIL) expression
levels in tumor samples for correlation with treatment outcomes. Thus far, none of
the above IHC expression levels have conclusively proven to be either prognostic or
predictive of response to treatment. In CHECKMATE 017, tumor expression of PD-L1 by
immunohistochemistry does not seems not to be predictive for OS or PFS benefit to
nivolumab [<xref rid="bibr8-1753465816661091" ref-type="bibr">Brahmer <italic>et
al.</italic> 2015</xref>]. However in CHECKMATE 057, PD-L1+ patients treated
with nivolumab was associated with an improved OS, PFS and duration of response at
the predefined 1%, 5%, and 10% cut-off points [<xref rid="bibr6-1753465816661091" ref-type="bibr">Borghaei <italic>et al.</italic> 2015</xref>].
These findings suggest there may inherent differences in the tumor microenvironment
between SCC <italic>versus</italic> nonsquamous cancer, consistent with the idea
that these are two distinct diseases. Inherent challenges are present in the use of
IHC expression levels, as differing antibodies and staining techniques may affect
scoring. There are currently no standard criteria across various anti PD-1 and PD-L1
trials in terms of reporting of a positive expression, making it even more
challenging to confirm the utility of IHC expression level with outcomes. To improve
on patient selection for ICIs, other biomarkers have been explored. Tumor mutation
and neo-antigen load are potentially promising predictive factors [<xref rid="bibr30-1753465816661091" ref-type="bibr">Schumacher and Schreiber,
2015</xref>]. However, the clinical applicability of this biomarker approach
remains to be defined.</p></sec><sec id="section7-1753465816661091"><title>Conclusion and future perspectives</title><p>The positive results of CHECKMATE 017 have established the role of nivolumab as a
superior option as compared with docetaxel in the second-line therapy in lung SCC.
Studies of nivolumab in first-line settings are ongoing and results are greatly
anticipated. Currently, many further studies are underway to investigate nivolumab&#x02019;s
role both as a single agent and as combination therapy at various lines of treatment
(<xref ref-type="table" rid="table5-1753465816661091">Table 5</xref>). These
studies will undoubtedly help to further define the role of nivolumab in the
treatment algorithm of NSCLC. However, undefined areas remain and are actively being
explored, including the role of ICIs in the adjuvant setting, in stage III following
chemotherapy and radiotherapy and duration of treatment. Further studies to
investigate predictive biomarkers and a better understanding of how we evaluate
treatment response will further help to optimize the outcomes of patients on
treatment.</p><table-wrap id="table5-1753465816661091" orientation="portrait" position="float"><label>Table 5.</label><caption><p>Overview on the treatment of immune-related toxicities, adapted from Spain
and colleagues [<xref rid="bibr33-1753465816661091" ref-type="bibr">Spain
<italic>et al.</italic> 2016</xref>], Naidoo and colleagues [<xref rid="bibr24-1753465816661091" ref-type="bibr">Naidoo <italic>et
al.</italic> 2015</xref>] and product insert [<xref rid="bibr9-1753465816661091" ref-type="bibr">Bristol-Myers-Squibb, 2016</xref>].</p></caption><alternatives><graphic xlink:href="10.1177_1753465816661091-table5"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Grade 1</th><th align="left" rowspan="1" colspan="1">Grade 2</th><th align="left" rowspan="1" colspan="1">Grade 3</th><th align="left" rowspan="1" colspan="1">Grade 4</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Skin</td><td rowspan="1" colspan="1">Topical steroid cream, antihistamines, can continue ICI</td><td rowspan="1" colspan="1">Initiate systemic steroids (prednisolone 0.5&#x02013;1 mg/kg/day) and
delay treatment until symptoms resolve to Grade 1</td><td rowspan="1" colspan="1">Hold ICI. Commence steroids (prednisolone 1&#x02013;2 mg/kg/day).
Dermatology consult for skin biopsy</td><td rowspan="1" colspan="1">Permanently discontinue ICI. Management as per Grade 3.</td></tr><tr><td rowspan="1" colspan="1">Gastrointestinal</td><td rowspan="1" colspan="1">Supportive measures, can continue ICI</td><td rowspan="1" colspan="1">Hold ICI. Commence steroids (prednisolone 0.5&#x02013;1 mg/kg/day) until
symptoms improve to Grade 1. If symptoms do not improve after 5
days, consider increasing steroids to 1&#x02013;2 mg/kg/day.</td><td rowspan="1" colspan="1">Hold ICI. Intravenous hydration, commence steroids (prednisolone
1&#x02013;2 mg/kg/day). Add infliximab 5 mg/kg if no improvement</td><td rowspan="1" colspan="1">Permanently discontinue ICI. Acute treatment as per Grade 3,
consider referral to gastroenterology and surgery for opinion in
management.</td></tr><tr><td rowspan="1" colspan="1">Pulmonary</td><td rowspan="1" colspan="1">Consider commencement of steroids (prednisolone 0.5&#x02013;1
mg/kg/day)</td><td rowspan="1" colspan="1">Hold ICI. Commence steroids (1&#x02013;2 mg/kg/day) until improvement.
consider empiric antibiotics.</td><td rowspan="1" colspan="1">Permanently discontinue ICI. High dose steroids (IV
methylprednisolone 2&#x02013;4 g/day) with empirical antibiotics. Add
immunomodulatory agent if no improvement after 48 h. referral to
pulmonologist for consideration of bronchoscopy.</td><td rowspan="1" colspan="1">Permanently discontinue ICI. Acute management as per Grade 3,
consider intensive care support</td></tr><tr><td rowspan="1" colspan="1">Thyroid dysfunction</td><td rowspan="1" colspan="1">Continue ICI. Monitor thyroid function</td><td rowspan="1" colspan="1">Hold ICI. Referral to endocrinology for further management</td><td rowspan="1" colspan="1">Permanently discontinue ICI. Commence steroids (Prednisolone 1&#x02013;2
mg/kg), referral to endocrinology for further management</td><td rowspan="1" colspan="1">Permanently discontinue ICI. Management as per Grade 3</td></tr><tr><td rowspan="1" colspan="1">Hepatitis</td><td rowspan="1" colspan="1">Continue ICI. Rule out other causes of hepatitis including
viral, metabolic and alcoholic causes</td><td rowspan="1" colspan="1">Hold ICI. Commence steroids (prednisolone 0.5&#x02013;1 mg/kg/day) until
symptoms improve to Grade 1.</td><td rowspan="1" colspan="1">Hold ICI, consider permanent discontinuation. Commence steroids
as per Grade 2.</td><td rowspan="1" colspan="1">Permanent discontinue ICI. Acute treatment as per Grade 3,
consider referral to hepatologist.</td></tr><tr><td rowspan="1" colspan="1">Renal</td><td rowspan="1" colspan="1">Can continue ICI. Supportive measures (encourage hydration,
monitor renal function, medication reconciliation to avoid
nephrotoxic drugs)</td><td rowspan="1" colspan="1">Hold ICI. Commence steroids (prednisolone 0.5&#x02013;1 mg/kg/day)</td><td rowspan="1" colspan="1">Permanently discontinue ICI, commence steroids (prednisolone 1&#x02013;2
mg/kg/day), consider high dose steroids. Referral to
nephrologist for further management</td><td rowspan="1" colspan="1">Permanently discontinue ICI. Acute management as per Grade 3,
consider acute hemodialysis</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn3-1753465816661091"><p>ICI, immune checkpoint inhibitor; IV, intravenous.</p></fn></table-wrap-foot></table-wrap><p>In conclusion, ICI has proven benefit in the treatment of metastatic NSCLC,
especially in the setting of SCC where targeted therapy with TKIs has not been
particularly effective. It is currently a treatment of choice post-progression on
platinum-based chemotherapy, and several studies are underway to examine its role in
a first-line setting and also in combination with chemotherapy and other
immunotherapeutic agents.</p></sec></body><back><ack><p>Ross Soo is supported by the National Research Foundation, Singapore and the
Singapore Ministry of Education under its Research Centers of Excellence initiative.
Joline Lim is supported by the National Medical Research Council, Singapore.</p></ack><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The author(s) disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: Ross Soo is supported
by the National Research Foundation Singapore and the Singapore Ministry of
Education under its Research Centres of Excellence initiative.</p></fn><fn fn-type="COI-statement"><p><bold>Conflict of interest statement:</bold> Joline Lim has no conflict of interest. Ross Soo has received honoraria from
Astra-Zeneca, Boehringer Ingelheim, Lilly, Merck, Novartis, Pfizer, and
Roche.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Akbay</surname><given-names>E.</given-names></name><name><surname>Koyama</surname><given-names>S.</given-names></name><name><surname>Carretero</surname><given-names>J.</given-names></name><name><surname>Altabef</surname><given-names>A.</given-names></name><name><surname>Tchaicha</surname><given-names>J.</given-names></name><name><surname>Christensen</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2013</year>) <article-title>Activation of the Pd-1
pathway contributes to immune escape in Egfr-driven lung
tumors</article-title>. <source>Cancer Discov</source>
<volume>3</volume>: <fpage>1355</fpage>&#x02013;<lpage>1363</lpage>.<pub-id pub-id-type="pmid">24078774</pub-id></mixed-citation></ref><ref id="bibr2-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ang</surname><given-names>Y.</given-names></name><name><surname>Tan</surname><given-names>H.</given-names></name><name><surname>Soo</surname><given-names>R.</given-names></name></person-group> (<year>2015</year>) <article-title>Best practice in the
treatment of advanced squamous cell lung cancer</article-title>.
<source>Ther Adv Respir Dis</source>
<volume>9</volume>: <fpage>224</fpage>&#x02013;<lpage>235</lpage>.<pub-id pub-id-type="pmid">25902866</pub-id></mixed-citation></ref><ref id="bibr3-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Antonia</surname><given-names>S.</given-names></name><name><surname>Brahmer</surname><given-names>J.</given-names></name><name><surname>Gettinger</surname><given-names>S.</given-names></name><name><surname>Chow</surname><given-names>L.</given-names></name><name><surname>Juergens</surname><given-names>R.</given-names></name><name><surname>Shepherd</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2014a</year>) <article-title>Nivolumab (Anti-Pd-1;
Bms-936558, Ono-4538) in combination with platinum-based doublet
chemotherapy (Pt-Dc) in advanced non-small cell lung cancer
(NSCLC)</article-title>. <source>Int J Radiat Oncol Biol Phys</source>
<volume>90</volume>: <fpage>S2</fpage>.</mixed-citation></ref><ref id="bibr4-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Antonia</surname><given-names>S.</given-names></name><name><surname>Gettinger</surname><given-names>S.</given-names></name><name><surname>Chow</surname><given-names>L.</given-names></name><name><surname>Juergens</surname><given-names>R.</given-names></name><name><surname>Borghaei</surname><given-names>H.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2014b</year>) <article-title>Nivolumab (Anti-Pd-1;
Bms-936558, Ono-4538) and ipilimumab in first-line non-small cell lung
cancer (NSCLC): Interim Phase 1 Results</article-title>. <source>J Clin
Oncol</source>
<volume>32</volume>(<issue>Suppl. 5</issue>):
<fpage>8023</fpage>.</mixed-citation></ref><ref id="bibr5-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Apetoh</surname><given-names>L.</given-names></name><name><surname>Tesniere</surname><given-names>A.</given-names></name><name><surname>Ghiringhelli</surname><given-names>F.</given-names></name><name><surname>Kroemer</surname><given-names>G.</given-names></name><name><surname>Zitvogel</surname><given-names>L.</given-names></name></person-group> (<year>2008</year>) <article-title>Molecular interactions
between dying tumor cells and the innate immune system determine the
efficacy of conventional anticancer therapies</article-title>.
<source>Cancer Res</source>
<volume>68</volume>: <fpage>4026</fpage>&#x02013;<lpage>4030</lpage>.<pub-id pub-id-type="pmid">18519658</pub-id></mixed-citation></ref><ref id="bibr6-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Borghaei</surname><given-names>H.</given-names></name><name><surname>Paz-Ares</surname><given-names>L.</given-names></name><name><surname>Horn</surname><given-names>L.</given-names></name><name><surname>Spigel</surname><given-names>D.</given-names></name><name><surname>Steins</surname><given-names>M.</given-names></name><name><surname>Ready</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2015</year>) <article-title>Nivolumab
<italic>versus</italic> docetaxel in advanced nonsquamous non-small cell
lung cancer</article-title>. <source>N Engl J Med</source>
<volume>373</volume>: <fpage>1627</fpage>&#x02013;<lpage>1639</lpage>.<pub-id pub-id-type="pmid">26412456</pub-id></mixed-citation></ref><ref id="bibr7-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brahmer</surname><given-names>J.</given-names></name><name><surname>Drake</surname><given-names>C.</given-names></name><name><surname>Wollner</surname><given-names>I.</given-names></name><name><surname>Powderly</surname><given-names>J.</given-names></name><name><surname>Picus</surname><given-names>J.</given-names></name><name><surname>Sharfman</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2010</year>) <article-title>Phase I study of
single-agent anti-programmed death-1 (Mdx-1106) in refractory solid tumors:
safety, clinical activity, pharmacodynamics, and immunologic
correlates</article-title>. <source>J Clin Oncol</source>
<volume>28</volume>: <fpage>3167</fpage>&#x02013;<lpage>3175</lpage>.<pub-id pub-id-type="pmid">20516446</pub-id></mixed-citation></ref><ref id="bibr8-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brahmer</surname><given-names>J.</given-names></name><name><surname>Reckamp</surname><given-names>K.</given-names></name><name><surname>Baas</surname><given-names>P.</given-names></name><name><surname>Crino</surname><given-names>L.</given-names></name><name><surname>Eberhardt</surname><given-names>W.</given-names></name><name><surname>Poddubskaya</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2015</year>) <article-title>Nivolumab
<italic>versus</italic> docetaxel in advanced squamous-cell non-small
cell lung cancer</article-title>. <source>N Engl J Med</source>
<volume>373</volume>: <fpage>123</fpage>&#x02013;<lpage>135</lpage>.<pub-id pub-id-type="pmid">26028407</pub-id></mixed-citation></ref><ref id="bibr9-1753465816661091"><mixed-citation publication-type="web">
<collab>Bristol-Myers-Squibb</collab> (<year>2016</year>) <article-title>Opdivo
Product Insert</article-title> (version revised 01/2016). Available at:
<ext-link ext-link-type="uri" xlink:href="http://packageinserts.bms.com/pi/pi_opdivo.pdf">http://packageinserts.bms.com/pi/pi_opdivo.pdf</ext-link>
(<comment>accessed 20 July 2016</comment>).</mixed-citation></ref><ref id="bibr10-1753465816661091"><mixed-citation publication-type="journal">
<collab>Cancer Genome Atlas Research</collab> (<year>2012</year>)
<article-title>Comprehensive genomic characterization of squamous cell lung
cancers</article-title>. <source>Nature</source>
<volume>489</volume>: <fpage>519</fpage>&#x02013;<lpage>525</lpage>.<pub-id pub-id-type="pmid">22960745</pub-id></mixed-citation></ref><ref id="bibr11-1753465816661091"><mixed-citation publication-type="journal">
<collab>Cancer Genome Atlas Research</collab> (<year>2014</year>)
<article-title>Comprehensive molecular profiling of lung
adenocarcinoma</article-title>. <source>Nature</source>
<volume>511</volume>: <fpage>543</fpage>&#x02013;<lpage>550</lpage>.<pub-id pub-id-type="pmid">25079552</pub-id></mixed-citation></ref><ref id="bibr12-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Curran</surname><given-names>M.</given-names></name><name><surname>Montalvo</surname><given-names>W.</given-names></name><name><surname>Yagita</surname><given-names>H.</given-names></name><name><surname>Allison</surname><given-names>J.</given-names></name></person-group> (<year>2010</year>) <article-title>Pd-1 and Ctla-4 combination
blockade expands infiltrating T-cells and reduces regulatory T and myeloid
cells within B16 melanoma tumors</article-title>. <source>Proc Natl Acad Sci
USA</source>
<volume>107</volume>: <fpage>4275</fpage>&#x02013;<lpage>4280</lpage>.<pub-id pub-id-type="pmid">20160101</pub-id></mixed-citation></ref><ref id="bibr13-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De la Cruz</surname><given-names>C.</given-names></name><name><surname>Tanoue</surname><given-names>L.</given-names></name><name><surname>Matthay</surname><given-names>R.</given-names></name></person-group> (<year>2011</year>) <article-title>Lung cancer: epidemiology,
etiology, and prevention</article-title>. <source>Clin Chest Med</source>
<volume>32</volume>: <fpage>605</fpage>&#x02013;<lpage>644</lpage>.<pub-id pub-id-type="pmid">22054876</pub-id></mixed-citation></ref><ref id="bibr14-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>D&#x02019;Incecco</surname><given-names>A.</given-names></name><name><surname>Andreozzi</surname><given-names>M.</given-names></name><name><surname>Ludovini</surname><given-names>V.</given-names></name><name><surname>Rossi</surname><given-names>E.</given-names></name><name><surname>Capodanno</surname><given-names>A.</given-names></name><name><surname>Landi</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2015</year>) <article-title>Pd-1 and Pd-L1 expression in
molecularly selected non-small cell lung cancer patients</article-title>.
<source>Br J Cancer</source>
<volume>112</volume>: <fpage>95</fpage>&#x02013;<lpage>102</lpage>.<pub-id pub-id-type="pmid">25349974</pub-id></mixed-citation></ref><ref id="bibr15-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garon</surname><given-names>E.</given-names></name><name><surname>Ciuleanu</surname><given-names>T.</given-names></name><name><surname>Arrieta</surname><given-names>O.</given-names></name><name><surname>Prabhash</surname><given-names>K.</given-names></name><name><surname>Syrigos</surname><given-names>K.</given-names></name><name><surname>Goksel</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2014</year>) <article-title>Ramucirumab plus docetaxel
<italic>versus</italic> placebo plus docetaxel for second-line treatment
of stage IV non-small-cell lung cancer after disease progression on
platinum-based therapy (revel): a multicentre, double-blind, randomised
phase 3 trial</article-title>. <source>Lancet</source>
<volume>384</volume>: <fpage>665</fpage>&#x02013;<lpage>673</lpage>.<pub-id pub-id-type="pmid">24933332</pub-id></mixed-citation></ref><ref id="bibr16-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gettinger</surname><given-names>S.</given-names></name><name><surname>Hellmann</surname><given-names>M.</given-names></name><name><surname>Shepherd</surname><given-names>F.</given-names></name><name><surname>Antonia</surname><given-names>S.</given-names></name><name><surname>Brahmer</surname><given-names>J.</given-names></name><name><surname>Goldman</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2015a</year>) <article-title>First-line monotherapy with
nivolumab in advanced non-small cell lung cancer: safety, efficacy and
correlation of outcomes with Pd-1 ligand expression</article-title>.
<source>J Clin Oncol</source>
<volume>33</volume>(<issue>suppl</issue>): abstr
8025.</mixed-citation></ref><ref id="bibr17-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gettinger</surname><given-names>S.</given-names></name><name><surname>Horn</surname><given-names>L.</given-names></name><name><surname>Gandhi</surname><given-names>L.</given-names></name><name><surname>Spigel</surname><given-names>D.</given-names></name><name><surname>Antonia</surname><given-names>S.</given-names></name><name><surname>Rizvi</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2015b</year>) <article-title>Overall survival and
long-term safety of nivolumab (anti-programmed death 1 antibody, Bms-936558,
Ono-4538) in patients with previously treated advanced non-small cell lung
cancer</article-title>. <source>J Clin Oncol</source>
<volume>33</volume>: <fpage>2004</fpage>&#x02013;<lpage>2012</lpage>.<pub-id pub-id-type="pmid">25897158</pub-id></mixed-citation></ref><ref id="bibr18-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gralla</surname><given-names>R.</given-names></name><name><surname>Coon</surname><given-names>C.</given-names></name><name><surname>Taylor</surname><given-names>F.</given-names></name><name><surname>Penrod</surname><given-names>J.</given-names></name><name><surname>Derosa</surname><given-names>M.</given-names></name><name><surname>Dastani</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2015</year>) <article-title>Evaluation of
disease-related symptoms in patients with advanced squamous non-small cell
lung cancer treated with nivolumab or docetaxel</article-title>. <source>J
Thorac Oncol</source>
<volume>10</volume>(<issue>Suppl 2</issue>):
<fpage>S233</fpage>.</mixed-citation></ref><ref id="bibr19-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Horn</surname><given-names>L.</given-names></name><name><surname>Rizvi</surname><given-names>N.</given-names></name><name><surname>Mazieres</surname><given-names>J.</given-names></name><name><surname>Planchard</surname><given-names>D.</given-names></name><name><surname>Stinchcombe</surname><given-names>T.</given-names></name><name><surname>Dy</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2015</year>) <article-title>Longer-term follow-up of a
phase 2 study (checkmate 063) of nivolumab in patients with advanced,
refractory squamous non-small cell lung cancer</article-title>. <source>J
Thorac Oncol</source>
<volume>10</volume>(<issue>Suppl 2</issue>):
<fpage>S175</fpage>.</mixed-citation></ref><ref id="bibr20-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hussein</surname><given-names>M.</given-names></name><name><surname>McCleod</surname><given-names>M.</given-names></name><name><surname>Chandler</surname><given-names>J.</given-names></name></person-group> (<year>2015</year>) <article-title>Safety and efficacy of
nivolumab in an ongoing trial of a Pd-L1+/- patient population with
metastatic non-small cell lung cancer</article-title>. <source>J Thorac
Oncol</source>
<volume>10</volume>(<issue>Suppl 2</issue>):
<fpage>S175</fpage>.</mixed-citation></ref><ref id="bibr21-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>E.</given-names></name><name><surname>Hirsh</surname><given-names>V.</given-names></name><name><surname>Mok</surname><given-names>T.</given-names></name><name><surname>Socinski</surname><given-names>M.</given-names></name><name><surname>Gervais</surname><given-names>R.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2008</year>) <article-title>Gefitinib
<italic>versus</italic> docetaxel in previously treated non-small cell
lung cancer (interest): a randomised phase III trial</article-title>.
<source>Lancet</source>
<volume>372</volume>: <fpage>1809</fpage>&#x02013;<lpage>1818</lpage>.<pub-id pub-id-type="pmid">19027483</pub-id></mixed-citation></ref><ref id="bibr22-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kris</surname><given-names>M.</given-names></name><name><surname>Johnson</surname><given-names>B.</given-names></name><name><surname>Berry</surname><given-names>L.</given-names></name><name><surname>Kwiatkowski</surname><given-names>D.</given-names></name><name><surname>Iafrate</surname><given-names>A.</given-names></name><name><surname>Wistuba</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2014</year>) <article-title>Using multiplexed assays of
oncogenic drivers in lung cancers to select targeted drugs</article-title>.
<source>JAMA</source>
<volume>31</volume>: <fpage>1998</fpage>&#x02013;<lpage>2006</lpage>.</mixed-citation></ref><ref id="bibr23-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kumarakulasinghe</surname><given-names>N.</given-names></name><name><surname>Van Zanwijk</surname><given-names>N.</given-names></name><name><surname>Soo</surname><given-names>R.</given-names></name></person-group> (<year>2015</year>) <article-title>Molecular targeted therapy in
the treatment of advanced stage non-small cell lung cancer
(NSCLC)</article-title>. <source>Respirology</source>
<volume>20</volume>: <fpage>370</fpage>&#x02013;<lpage>378</lpage>.<pub-id pub-id-type="pmid">25689095</pub-id></mixed-citation></ref><ref id="bibr24-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Naidoo</surname><given-names>J.</given-names></name><name><surname>Page</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Connell</surname><given-names>L.</given-names></name><name><surname>Schindler</surname><given-names>K.</given-names></name><name><surname>Lacouture</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2015</year>) <article-title>Toxicities of the anti-Pd-1
and anti-Pd-L1 immune checkpoint antibodies</article-title>. <source>Ann
Oncol</source>
<volume>26</volume>: <fpage>2375</fpage>&#x02013;<lpage>2391</lpage>.<pub-id pub-id-type="pmid">26371282</pub-id></mixed-citation></ref><ref id="bibr25-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakagawa</surname><given-names>K. M.</given-names></name><name><surname>Sakai</surname><given-names>H.</given-names></name><name><surname>Nogami</surname><given-names>N.</given-names></name><name><surname>Atagi</surname><given-names>S.</given-names></name><name><surname>Takahashi</surname><given-names>T.</given-names></name><name><surname>Nishio</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2015</year>) <article-title>Phase II studies of
nivolumab in patients with advanced squamous (SQ) or nonsquamous (NSQ)
non-small cell lung cancer (NSCLC)</article-title>. <source>J Thorac
Oncol</source>
<volume>10</volume>(<issue>Suppl 2</issue>):
<fpage>S270</fpage>.</mixed-citation></ref><ref id="bibr26-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nishino</surname><given-names>M.</given-names></name><name><surname>Sholl</surname><given-names>L.</given-names></name><name><surname>Hodi</surname><given-names>F.</given-names></name><name><surname>Hatabu</surname><given-names>H.</given-names></name><name><surname>Ramaiya</surname><given-names>N.</given-names></name></person-group> (<year>2015</year>) <article-title>Anti-Pd-1-related pneumonitis
during cancer immunotherapy</article-title>. <source>N Engl J Med</source>
<volume>373</volume>: <fpage>288</fpage>&#x02013;<lpage>290</lpage>.<pub-id pub-id-type="pmid">26176400</pub-id></mixed-citation></ref><ref id="bibr27-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reck</surname><given-names>M.</given-names></name><name><surname>Kaiser</surname><given-names>R.</given-names></name><name><surname>Mellemgaard</surname><given-names>A.</given-names></name><name><surname>Douillard</surname><given-names>J.</given-names></name><name><surname>Orlov</surname><given-names>S.</given-names></name><name><surname>Krzakowski</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2014</year>) <article-title>Docetaxel plus nintedanib
<italic>versus</italic> docetaxel plus placebo in patients with
previously treated non-small-cell lung cancer (Lume-Lung 1): a phase 3,
double-blind, randomised controlled trial</article-title>. <source>Lancet
Oncol</source>
<volume>15</volume>: <fpage>143</fpage>&#x02013;<lpage>155</lpage>.<pub-id pub-id-type="pmid">24411639</pub-id></mixed-citation></ref><ref id="bibr28-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rizvi</surname><given-names>N.</given-names></name><name><surname>Mazieres</surname><given-names>J.</given-names></name><name><surname>Planchard</surname><given-names>D.</given-names></name><name><surname>Stinchcombe</surname><given-names>T.</given-names></name><name><surname>Dy</surname><given-names>G.</given-names></name><name><surname>Antonia</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2015</year>) <article-title>Activity and safety of
nivolumab, an anti-pd-1 immune checkpoint inhibitor, for patients with
advanced, refractory squamous non-small-cell lung cancer (checkmate 063): a
phase 2, single-arm trial</article-title>. <source>Lancet Oncol</source>
<volume>16</volume>: <fpage>257</fpage>&#x02013;<lpage>265</lpage>.<pub-id pub-id-type="pmid">25704439</pub-id></mixed-citation></ref><ref id="bibr29-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rizvi</surname><given-names>N.</given-names></name><name><surname>Quan</surname><given-names>L.</given-names></name><name><surname>Borghaei</surname><given-names>H.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Harbison</surname><given-names>C.</given-names></name><name><surname>Alparthy</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2014</year>) <article-title>Safety and response with
nivolumab (anti-Pd-1; Bms-936558, Ono-4538) plus erlotinib in patients (Pts)
with epidermal growth factor receptor mutant (EGFR MT) advanced
NSCLC</article-title>. <source>J Clin Oncol</source>
<volume>32</volume>(<issue>Suppl. 5</issue>):
<fpage>8022</fpage>.</mixed-citation></ref><ref id="bibr30-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schumacher</surname><given-names>T.</given-names></name><name><surname>Schreiber</surname><given-names>R.</given-names></name></person-group> (<year>2015</year>) <article-title>Neoantigens in cancer
immunotherapy</article-title>. <source>Science</source>
<volume>348</volume>: <fpage>69</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">25838375</pub-id></mixed-citation></ref><ref id="bibr31-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shepherd</surname><given-names>F.</given-names></name><name><surname>Dancey</surname><given-names>J.</given-names></name><name><surname>Ramlau</surname><given-names>R.</given-names></name><name><surname>Mattson</surname><given-names>K.</given-names></name><name><surname>Gralla</surname><given-names>R.</given-names></name><name><surname>O&#x02019;Rourke</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2000</year>) <article-title>Prospective randomized trial
of docetaxel <italic>versus</italic> best supportive care in patients with
non-small cell lung cancer previously treated with platinum-based
chemotherapy</article-title>. <source>J Clin Oncol</source>
<volume>18</volume>: <fpage>2095</fpage>&#x02013;<lpage>2103</lpage>.<pub-id pub-id-type="pmid">10811675</pub-id></mixed-citation></ref><ref id="bibr32-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Soria</surname><given-names>J.</given-names></name><name><surname>Felip</surname><given-names>E.</given-names></name><name><surname>Cobo</surname><given-names>M.</given-names></name><name><surname>Lu</surname><given-names>S.</given-names></name><name><surname>Syrigos</surname><given-names>K.</given-names></name><name><surname>Lee</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2015</year>) <article-title>Afatinib
<italic>versus</italic> erlotinib as second-line treatment of patients
with advanced squamous cell carcinoma of the lung (Lux-Lung 8): an
open-label randomised controlled phase 3 trial</article-title>.
<source>Lancet Oncol</source>
<volume>16</volume>: <fpage>897</fpage>&#x02013;<lpage>907</lpage>.<pub-id pub-id-type="pmid">26156651</pub-id></mixed-citation></ref><ref id="bibr33-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spain</surname><given-names>L.</given-names></name><name><surname>Diem</surname><given-names>S.</given-names></name><name><surname>Larkin</surname><given-names>J.</given-names></name></person-group> (<year>2016</year>) <article-title>Management of toxicities of
immune checkpoint inhibitors</article-title>. <source>Cancer Treat
Rev</source>
<volume>44</volume>: <fpage>51</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">26874776</pub-id></mixed-citation></ref><ref id="bibr34-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sundar</surname><given-names>R.</given-names></name><name><surname>Cho</surname><given-names>B.</given-names></name><name><surname>Brahmer</surname><given-names>J.</given-names></name><name><surname>Soo</surname><given-names>R.</given-names></name></person-group> (<year>2015</year>) <article-title>Nivolumab in NSCLC: latest
evidence and clinical potential</article-title>. <source>Ther Adv Med
Oncol</source>
<volume>7</volume>: <fpage>85</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">25755681</pub-id></mixed-citation></ref><ref id="bibr35-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thatcher</surname><given-names>N.</given-names></name><name><surname>Hirsch</surname><given-names>F.</given-names></name><name><surname>Luft</surname><given-names>A.</given-names></name><name><surname>Szczesna</surname><given-names>A.</given-names></name><name><surname>Ciuleanu</surname><given-names>T.</given-names></name><name><surname>Dediu</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2015</year>) <article-title>Necitumumab plus gemcitabine
and cisplatin <italic>versus</italic> gemcitabine and cisplatin alone as
first-line therapy in patients with stage IV squamous non-small cell lung
cancer (squire): an open-label, randomised, controlled phase 3
trial</article-title>. <source>Lancet Oncol</source>
<volume>16</volume>: <fpage>763</fpage>&#x02013;<lpage>774</lpage>.<pub-id pub-id-type="pmid">26045340</pub-id></mixed-citation></ref><ref id="bibr36-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Topalian</surname><given-names>S.</given-names></name><name><surname>Hodi</surname><given-names>F.</given-names></name><name><surname>Brahmer</surname><given-names>J.</given-names></name><name><surname>Gettinger</surname><given-names>S.</given-names></name><name><surname>Smith</surname><given-names>D.</given-names></name><name><surname>Mcdermott</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2012</year>) <article-title>Safety, activity, and immune
correlates of anti-Pd-1 antibody in cancer</article-title>. <source>N Engl J
Med</source>
<volume>366</volume>: <fpage>2443</fpage>&#x02013;<lpage>2454</lpage>.<pub-id pub-id-type="pmid">22658127</pub-id></mixed-citation></ref><ref id="bibr37-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Torri</surname><given-names>V.</given-names></name><name><surname>Ando</surname><given-names>M.</given-names></name><name><surname>Rulli</surname><given-names>E.</given-names></name><name><surname>Floriani</surname><given-names>I.</given-names></name><name><surname>Kawaguchi</surname><given-names>T.</given-names></name><name><surname>Isa</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2015</year>) <article-title>Individual patients data
analysis (IPD) of three randomized studies comparing erlotinib (E) with
chemotherapy (CT) in patients with advanced wild-type epidermal growth
factor receptor (WTEGFR) non-small cell lung cancer (NSCLC)</article-title>.
<source>J Clin Oncol</source>
<volume>33</volume>: abstr 8048.</mixed-citation></ref><ref id="bibr38-1753465816661091"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Thudium</surname><given-names>K.</given-names></name><name><surname>Han</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Feingersh</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2014</year>) <article-title>In vitro characterization of
the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in
non-human primates</article-title>. <source>Cancer Immunol Res</source>
<volume>2</volume>: <fpage>846</fpage>&#x02013;<lpage>856</lpage>.<pub-id pub-id-type="pmid">24872026</pub-id></mixed-citation></ref></ref-list></back></article>